Schubert Firm Investigates Impax Laboratories' Top Executives

Schubert Jonckheer & Kolbe LLP is actively investigating alleged misconduct by Impax Laboratories Inc.’s (NASDAQ: IPXL) top executives, including claims that Impax’s officers and directors breached their fiduciary duties to the company.

The Schubert firm’s investigation concerns whether Impax’s officers and directors breached their fiduciary duties in connection with (a) Impax’s responses to various Food and Drug Administration (“FDA”) notices and warnings regarding problems in the manufacturing and quality control processes at Impax’s production facilities; (b) the oversight of Impax’s business; and (c) Impax’s disclosures to its shareholders concerning the state of affairs at Impax.
 
Impax shareholders may have the option to pursue a shareholder derivative action through which shareholders may hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.

If you currently own Impax stock and wish to obtain additional information about the investigation and your legal rights, please fill out our form (at right) or contact Dustin Schubert either via email at dschubert@schubertlawfirm.com or by phone at 415-788-4220.